+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia-Pacific Cancer Diagnostics Market, By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others), By Technology, By Application, By End-User, By Country, Competition Forecast & Opportunities, 2027

  • PDF Icon

    Report

  • 86 Pages
  • July 2022
  • Region: Asia Pacific
  • TechSci Research
  • ID: 5632994
Free Webex Call
10% Free customization

Asia-Pacific cancer diagnostics market is expected to grow at a steady CAGR during the forecast period on account of the increasing trend of unhealthy diet amongst the population and the growing number of cancer cases in the region

Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

Asia-Pacific cancer diagnostics market is expected to grow at a steady CAGR during the forecast period on account of the increasing trend of unhealthy diet amongst the population and the growing number of cancer cases in the region. This, in turn, is propelling the market growth. Furthermore, growing efforts undertaken by the government to create awareness regarding cancer, as well as to minimize the disease burden, are anticipated to positively impact the growth of the market through 2027. Surging demand for screening tools and techniques is further spurring the growth of the market. However, the high cost of diagnosis might hamper the growth of the market during the forecast period. Furthermore, several side effects associated with imaging solutions are expected to impede the market's growth over the next few years.

The Asia-Pacific cancer diagnostics market is segmented on diagnostic type, technology, application, end-user, company, and country. Based on diagnostic type, the market is categorized into lab testing, genetic testing, imaging testing, biomarkers testing, in vitro diagnostic testing, biopsy, and others. The imaging testing segment dominated the market until 2021 and is expected to dominate the market during the forecast period as well. This dominance can be ascribed to the fact that imaging modalities such as computed tomography scans and magnetic resonance imaging are quick, non-invasive, and pain-free diagnostic solutions. In addition to this, technological advancements in imaging modalities have contributed to the segmental growth. Based on end-user, the market can be fragmented into diagnostic centers, hospitals and clinics, research institutes, and others. The hospitals and clinics segment is expected to dominate the market during the forecast period on account of increased rates of adoption of technologically advanced imaging modalities and other devices which are used in the detection of cancer.

The major players operating in the Asia-Pacific cancer diagnostics market are Thermo Fisher Scientific, Inc., GE Healthcare (A Subsidiary of General Electric Company), Abbott Laboratories, Inc., Becton, Dickinson and Company, Siemens AG, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Bio Rad Laboratories Inc., Illumina, Inc., Boehringer Ingelheim International GmbH, and others. Major companies are developing advanced technologies and launching new products to stay competitive in the market. Other competitive strategies include mergers & acquisitions, partnerships, agreements, and new developments in order to expand their geographic reach and increase customer base.

Years considered for this report:

  • Historical Years: 2017-2020
  • Base Year: 2021
  • Estimated Year: 2022E
  • Forecast Period: 2023F-2027F

Objective of the Study:

  • To analyze the historical growth in the market size of Asia-Pacific cancer diagnostics market from 2017 to 2021.
  • To estimate and forecast the market size of Asia-Pacific cancer diagnostics market from 2022E to 2027F and growth rate until 2027F.
  • To classify and forecast Asia-Pacific cancer diagnostics market based on diagnostic type, technology, application, end-user, company, and country.
  • To identify dominant country or segment in the Asia-Pacific cancer diagnostics market.
  • To identify drivers and challenges for Asia-Pacific cancer diagnostics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in Asia-Pacific cancer diagnostics market.
  • To conduct pricing analysis for Asia-Pacific cancer diagnostics market.
  • To identify and analyze the profiles of leading players operating in Asia-Pacific cancer diagnostics market.
  • To identify key sustainable strategies adopted by market players in Asia-Pacific cancer diagnostics market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, the publisher sourced a list of major diagnostic players and hospital chains across the region. Subsequently, the publisher conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the hospitals/clinics which could not be identified due to the limitations of secondary research. The publisher analyzed the products and presence of all major players across the region.

The publisher calculated the market size of the Asia-Pacific cancer diagnostics market using a bottom-up approach, wherein data for various end-user segments were recorded and forecast for the future years. The publisher sourced these values from the industry experts and company representatives and externally validated them through analyzing historical data of these services for getting an appropriate overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations, and financial reports were also studied by the publisher.

Key Target Audience:

  • Cancer diagnostic hospitals, diagnostic laboratories, and other stakeholders
  • Market research and consulting firms
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums, and alliances related to cancer diagnostics
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as major diagnostic players and hospital chains, besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, Asia-Pacific cancer diagnostics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Asia-Pacific Cancer Diagnostics Market, By Diagnostic Type:

  • Lab Testing
  • Genetic Testing
  • Imaging Testing
  • Biomarkers Testing
  • In Vitro Diagnostic Testing
  • Biopsy
  • Others

Asia-Pacific Cancer Diagnostics Market, By Technology:

  • Platform Based
  • Instrument Based
  • Tumor Biomarker Tests

Asia-Pacific Cancer Diagnostics Market, By Application:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Kidney Cancer
  • Skin Cancer
  • Others

Asia-Pacific Cancer Diagnostics Market, By End-User:

  • Diagnostic Centers
  • Hospitals and Clinics
  • Research Institutes
  • Others

Asia Pacific Cancer Diagnostics Market, By Country:

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Singapore
  • Malaysia
  • Indonesia
  • Philippines
  • Thailand

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in Asia-Pacific cancer diagnostics market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Service Overview2. Research Methodology3. Executive Summary4. Impact of COVID-19 on Asia-Pacific Cancer Diagnostics Market5. Voice of Customer
6. Asia-Pacific Cancer Diagnostics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others)
6.2.2. By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests)
6.2.3. By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others)
6.2.4. By End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others)
6.2.5. By Company (2021)
6.2.6. By Country
6.3. Market Map
6.4. Asia-Pacific: Country Analysis
6.4.1. China Cancer Diagnostics Market Outlook
6.4.1.1. Market Size & Forecast
6.4.1.1.1. By Value
6.4.1.2. Market Share & Forecast
6.4.1.2.1. By Diagnostic Type
6.4.1.2.2. By Technology
6.4.1.2.3. By Application
6.4.1.2.4. By End User
6.4.2. India Cancer Diagnostics Market Outlook
6.4.2.1. Market Size & Forecast
6.4.2.1.1. By Value
6.4.2.2. Market Share & Forecast
6.4.2.2.1. By Diagnostic Type
6.4.2.2.2. By Technology
6.4.2.2.3. By Application
6.4.2.2.4. By End User
6.4.3. Japan Cancer Diagnostics Market Outlook
6.4.3.1. Market Size & Forecast
6.4.3.1.1. By Value
6.4.3.2. Market Share & Forecast
6.4.3.2.1. By Diagnostic Type
6.4.3.2.2. By Technology
6.4.3.2.3. By Application
6.4.3.2.4. By End User
6.4.4. South Korea Cancer Diagnostics Market Outlook
6.4.4.1. Market Size & Forecast
6.4.4.1.1. By Value
6.4.4.2. Market Share & Forecast
6.4.4.2.1. By Diagnostic Type
6.4.4.2.2. By Technology
6.4.4.2.3. By Application
6.4.4.2.4. By End User
6.4.5. Australia Cancer Diagnostics Market Outlook
6.4.5.1. Market Size & Forecast
6.4.5.1.1. By Value
6.4.5.2. Market Share & Forecast
6.4.5.2.1. By Diagnostic Type
6.4.5.2.2. By Technology
6.4.5.2.3. By Application
6.4.5.2.4. By End User
6.4.6. Singapore Cancer Diagnostics Market Outlook
6.4.6.1. Market Size & Forecast
6.4.6.1.1. By Value
6.4.6.2. Market Share & Forecast
6.4.6.2.1. By Diagnostic Type
6.4.6.2.2. By Technology
6.4.6.2.3. By Application
6.4.6.2.4. By End User
6.4.7. Malaysia Cancer Diagnostics Market Outlook
6.4.7.1. Market Size & Forecast
6.4.7.1.1. By Value
6.4.7.2. Market Share & Forecast
6.4.7.2.1. By Diagnostic Type
6.4.7.2.2. By Technology
6.4.7.2.3. By Application
6.4.7.2.4. By End User
6.4.8. Indonesia Cancer Diagnostics Market Outlook
6.4.8.1. Market Size & Forecast
6.4.8.1.1. By Value
6.4.8.2. Market Share & Forecast
6.4.8.2.1. By Diagnostic Type
6.4.8.2.2. By Technology
6.4.8.2.3. By Application
6.4.8.2.4. By End User
6.4.9. Philippines Cancer Diagnostics Market Outlook
6.4.9.1. Market Size & Forecast
6.4.9.1.1. By Value
6.4.9.2. Market Share & Forecast
6.4.9.2.1. By Diagnostic Type
6.4.9.2.2. By Technology
6.4.9.2.3. By Application
6.4.9.2.4. By End User
6.4.10. Thailand Cancer Diagnostics Market Outlook
6.4.10.1. Market Size & Forecast
6.4.10.1.1. By Value
6.4.10.2. Market Share & Forecast
6.4.10.2.1. By Diagnostic Type
6.4.10.2.2. By Technology
6.4.10.2.3. By Application
6.4.10.2.4. By End User
7. Market Dynamics
7.1. Drivers
7.2. Challenges
8. Market Trends & Developments9. Asia-Pacific Economic Profile10. Policy & Regulatory Landscape
11. Competitive Landscape
11.1. Thermo Fisher Scientific, Inc.
11.2. GE Healthcare (A Subsidiary of General Electric Company)
11.3. Abbott Laboratories, Inc.
11.4. Becton, Dickinson and Company
11.5. Siemens AG
11.6. Agilent Technologies, Inc.
11.7. F. Hoffmann-La Roche Ltd.
11.8. Bio Rad Laboratories Inc.
11.9. Illumina, Inc.
11.10. Boehringer Ingelheim International GmbH
12. Strategic Recommendations

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Thermo Fisher Scientific, Inc
  • GE Healthcare (A Subsidiary of General Electric Company)
  • Abbott Laboratories, Inc
  • Becton, Dickinson and Company
  • Siemens AG
  • Agilent Technologies, Inc
  • F Hoffmann-La Roche Ltd
  • Bio Rad Laboratories Inc
  • Illumina, Inc
  • Boehringer-Ingelheim International GmbH